Application of dabrafenib and/or medicinal derivative thereof in preparation of anti-arenavirus drug

A technology of arenavirus and its derivatives, applied in the field of medicine, can solve the problems of limited therapeutic effect and strong side effects of anti-arenavirus drugs

Active Publication Date: 2020-11-24
CANVEST WUHAN BIOTECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to overcome the problems that existing anti-arenavirus drugs have limited therapeutic effects and strong side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dabrafenib and/or medicinal derivative thereof in preparation of anti-arenavirus drug
  • Application of dabrafenib and/or medicinal derivative thereof in preparation of anti-arenavirus drug
  • Application of dabrafenib and/or medicinal derivative thereof in preparation of anti-arenavirus drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] This example studies the cytotoxicity of the target compound dabrafenib, and the specific process is as follows:

[0026] BHK-21 cells and Vero cells were divided into 1.5×10 4 Cells / well were seeded in 96-well cell culture plates at 37°C, 5% CO 2 After culturing in the incubator for 12-16 hours, replace the medium with DMEM medium containing 2% FBS, and then use dabrafenib at a concentration of 0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, 32 μM, 64 μM and 128 μM For treatment, add the same volume of DMSO to the negative control, set three replicate wells for each concentration, incubate at 37°C for 36 hours, and set up zero-adjustment wells with only medium and no cells. Discard the supernatant, wash once with PBS, add 50 μl of 0.5% MTT PBS solution to each well, and place it at 37°C for 4 hours in the dark, and you can observe blue-purple crystals appearing on the bottom of the plate, and stop the culture at this time. And carefully aspirate the supernatant, add 100 μl DM...

Embodiment 2

[0029] This example studies the antiviral activity of the target compound dabrafenib against arenavirus (LCMV), the specific process is as follows:

[0030] BHK-21 cells and Vero cells were divided into 1.5×10 4 Cells / well were seeded in 96-well cell culture plates at 37°C, 5% CO 2 After culturing in the incubator for 12-16 hours, replace the medium with DMEM medium containing 2% FBS, and then use dabrafenib at a concentration of 0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, 32 μM, 64 μM and 128 μM For treatment, the same volume of DMSO was added to the negative control, and three replicate wells were set for each concentration. After incubation for 1 h, the cells were infected with LCMV. After 36h, the effect of dabrafenib inhibiting virus replication was detected by measuring the supernatant titer, and the results on the two kinds of cells were as follows: Figure 5 and Figure 6 As shown, under different concentration conditions, the compound dabrafenib has a significant inhib...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of dabrafenib and / or a medicinal derivative thereof in preparation of an anti-arenavirus drug. By detecting the cytotoxicity of the dabrafenib on Vero cells and BHK-21 cells and the antiviral activity of the dabrafenib on arenavirus, it is indicated that the dabrafenib shows a relatively high arenavirus resisting effect on the cellular level, and a new direction is provided for prevention and treatment of arenavirus infectious diseases.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of dabrafenib and / or its pharmaceutically acceptable derivatives in the preparation of anti-arenavirus drugs. Background technique [0002] Mammalian arenaviruses (Mammarenavirus) belong to the Bunyavirales (Bunyavirales) arenaviridae (Arenaviridae), mainly composed of Old World and New World arenaviruses, including many virulent viruses that have important threats to humans, such as La Lassa virus (LASV), Junín virus (JUNV), Machupo virus (MACV), etc. Among them, LASV is mainly prevalent in Nigeria, Liberia, Sierra Leone, Guinea and other West African countries. Every year, 100,000 to 300,000 people are infected and about 5,000 people die. JUNV is mainly prevalent in the Pampa region of Argentina, causing Argentine hemorrhagic fever with a fatality rate of 15%-30%. In addition, Lymphocyticchoriomeningitis virus (LCMV) exists in my country, mainly i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/506A61P31/14
CPCA61K31/506A61P31/14
Inventor 徐国东刘愈杰幸晓莹
Owner CANVEST WUHAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap